Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer-Reference-Cited by-同舟云学术

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer

Published:2010-11-10 Issue:9 Volume:117 Page:1837-1846
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Musolino Antonino,Ciccolallo Laura,Panebianco Michele,Fontana Elisa,Zanoni Daniele,Bozzetti Cecilia,Michiara Maria,Silini Enrico Maria,Ardizzoni Andrea

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25771/fullpdf

Reference49 articles.

1. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System;Barnholtz-Sloan;J Clin Oncol,2004

2. Breast carcinoma: pattern of metastasis at autopsy;Lee;J Surg Oncol,1983

3. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG);Pestalozzi;Ann Oncol,2006

4. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge;Stemmler;Oncologist,2008

5. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment;Gonzalez-Angulo;Cancer,2004

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab-induced optic neuritis: “blindness” side effect;Journal of Oncology Pharmacy Practice;2024-08-14

2. Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study;Clinical Breast Cancer;2024-08

3. Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis;ESMO Open;2024-01

4. Early detection of brain metastases and appropriate local therapy followed by systemic chemotherapy may improve the prognosis of gastric cancer;Scientific Reports;2023-11-27

5. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy;Breast Cancer;2023-11-01